Abstract
This review focuses on the synthesis and mechanisms of antitumor activity of cationic nonphosphorus analogs of edelfosine. The role of variable length and mode of conjugation of the spacer group, the types of cationic head, and the length of the substituent at C(2) atom of the glycerol backbone are discussed, providing the basis for rational design of lipophilic anticancer drugs, in particular, for elimination of multidrug resistant cells.
Keywords: Ether lipids, Non-phosphorus cationic glycerolipids, Anticancer drugs, Edelfosine (ET-18-OMe)
Mini-Reviews in Medicinal Chemistry
Title: Ether Lipids as Anticancer Agents: Focus on Non-Phosphorus Cationic Glycerolipids
Volume: 6 Issue: 5
Author(s): N. V. Plyavnik, A. A. Shtil and G. A. Serebrennikova
Affiliation:
Keywords: Ether lipids, Non-phosphorus cationic glycerolipids, Anticancer drugs, Edelfosine (ET-18-OMe)
Abstract: This review focuses on the synthesis and mechanisms of antitumor activity of cationic nonphosphorus analogs of edelfosine. The role of variable length and mode of conjugation of the spacer group, the types of cationic head, and the length of the substituent at C(2) atom of the glycerol backbone are discussed, providing the basis for rational design of lipophilic anticancer drugs, in particular, for elimination of multidrug resistant cells.
Export Options
About this article
Cite this article as:
Plyavnik V. N., Shtil A. A. and Serebrennikova A. G., Ether Lipids as Anticancer Agents: Focus on Non-Phosphorus Cationic Glycerolipids, Mini-Reviews in Medicinal Chemistry 2006; 6 (5) . https://dx.doi.org/10.2174/138955706776876221
DOI https://dx.doi.org/10.2174/138955706776876221 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Current Cancer Drug Targets Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics Secondary Metabolites from Cyanobacteria: Complex Structures and Powerful Bioactivities
Current Organic Chemistry Lifelong and Prenatal Effects of Phytoestrogens
Current Bioactive Compounds Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy (Part I)
Current Gene Therapy Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets Efficacy and Safety of Robot-assisted Thoracic Surgery (RATS) Compare with Video-assisted Thoracoscopic Surgery (VATS) for Lung Lobectomy in Patients with Non-small Cell Lung Cancer
Combinatorial Chemistry & High Throughput Screening Peptide Sequence-Dominated Enzyme-Responsive Nanoplatform for Anticancer Drug Delivery
Current Topics in Medicinal Chemistry Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Mini-Reviews in Medicinal Chemistry Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies The Anterior Gradient-2 Pathway as a Model for Developing Peptide-Aptamer Anti-Cancer Drug Leads that Stimulate p53 Function
Current Chemical Biology Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design